{ "meta": { "data_length": 1, "message": "Statement id stmt:ema:erbitux:4:0 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Aerbitux%3A4%3A0", "status": "success", "status_code": 200, "timestamp_elapsed": 0.002049, "timestamp_received": "2026-10-16T23:35:35.669291+00:00Z", "timestamp_returned": "2026-10-16T23:35:35.671340+00:00Z", "trace_id": "023d7a61-bd40-4025-81e7-7c8961a737be" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:ema:erbitux:4:0", "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized cetuximab in combination with encorafenib for the treatment of patients with BRAF V600E mutant metastatic colorectal cancer who have received prior systemic therapy.", "contributions": [ { "id": "ctrb:vanallenlab:2026-08-02:0", "type": "Contribution", "description": "Initial curation of into moalmanac-db", "date": "2026-08-02", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2026-06-25:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2026-06-25", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:erbitux", "type": "Document", "documentType": "Regulatory approval", "name": "Erbitux (cetuximab) [product information]. EMA.", "title": null, "aliases": [], "description": "Merck Europe B.V. Erbitux (cetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf. Revised July 2026. Accessed August 2, 2026.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Merck Europe B.V.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Erbitux", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "cetuximab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2009-07-14", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2026-07-15", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:81", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C5105", "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Colorectal+Adenocarcinoma+%28COADREAD%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C5105", "code": "C5105", "name": "Colorectal Adenocarcinoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C5105" ] } }, "objectTherapeutic": { "id": "txgrp:16", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C98283", "conceptType": "Therapy", "name": "Encorafenib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2049106", "code": "2049106", "name": "encorafenib", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2049106" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1559914", "code": "1559914", "name": "encorafenib", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1559914" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "B-RAF inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C98283", "code": "C98283", "name": "Encorafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283" ] } }, { "id": "tx:ncit:C1723", "conceptType": "Therapy", "name": "Cetuximab", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:318341", "code": "318341", "name": "cetuximab", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=318341" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1315411", "code": "1315411", "name": "cetuximab", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1315411" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "EGFR inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C1723", "code": "C1723", "name": "Cetuximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:16", "present": true, "subject": { "id": "bmkr:16", "type": "CategoricalVariant", "name": "BRAF p.V600E", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "type": "Allele", "name": "NP_004324.2:p.Val600Glu", "aliases": [ "NP_004324.2:p.V600E", "BRAF p.V600E" ], "description": "VRS variation of NP_004324.2:p.Val600Glu", "digest": "j4XnsLZcdzDIYa5pvvXM7t1wn9OITr0L", "expressions": [ { "syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Glu", "extensions": [ { "name": "hgvs.p_short", "value": "p.V600E" } ] } ], "location": { "id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 600 of the Refseq protein NP_004324.2, which is the protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6).", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": { "id": "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "type": "SequenceReference", "name": "NP_004324.2", "aliases": [ "ensembl:ENSP00000288602.6", "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "refseq:NP_004324.2" ], "description": "The protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6), corresponding to the Refseq protein accession NP_004324.2.", "moleculeType": "protein", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "residueAlphabet": "aa" }, "start": 599, "end": 600, "sequence": "V" }, "state": { "type": "LiteralSequenceExpression", "sequence": "E" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:1097", "conceptType": "Gene", "name": "BRAF", "primaryCoding": { "id": "coding:hgnc:1097", "code": "HGNC:1097", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000157764", "code": "ENSG00000157764", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000157764" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:673", "code": "673", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/673" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004333.6", "code": "NM_004333.6", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "7" }, { "name": "start_position", "value": 140453136 }, { "name": "end_position", "value": 140453136 }, { "name": "reference_allele", "value": "A" }, { "name": "alternate_allele", "value": "T" }, { "name": "cdna_change", "value": "c.1799T>A" }, { "name": "protein_change", "value": "p.V600E" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 15 }, { "name": "rsid", "value": "rs113488022" }, { "name": "hgvsg", "value": "7:g.140453136A>T" }, { "name": "hgvsc", "value": "ENST00000288602.6:c.1799T>A" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:ema:erbitux:4", "type": "Indication", "description": "Erbitux is indicated for the treatment of adult patients with BRAF V600E mutant metastatic colorectal cancer in combination with encorafenib in patients who have received prior systemic therapy.", "contributions": [ { "id": "ctrb:vanallenlab:2026-08-02:0", "type": "Contribution", "description": "Initial curation of into moalmanac-db", "date": "2026-08-02", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2026-06-25:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2026-06-25", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:erbitux", "type": "Document", "documentType": "Regulatory approval", "name": "Erbitux (cetuximab) [product information]. EMA.", "title": null, "aliases": [], "description": "Merck Europe B.V. Erbitux (cetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf. Revised July 2026. Accessed August 2, 2026.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Merck Europe B.V.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Erbitux", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "cetuximab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2009-07-14", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2026-07-15", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }